Quantech Spółka z Ograniczoną Odpowiedzialnością (KRS 0000638534, NIP 1182129940) is a Polish company, headquartered in Izabelin B, Mazowieckie voivodeship. QUANTECH operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since September 23, 2016. QUANTECH's most recently reported net revenue was 0 PLN for 2020. QUANTECH's operations are currently suspended.
The company is currently suspended
Suspended since December 1, 2025
Negative equity
Negative equity in 2 of 2 available reporting years.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Quantech
Identity
- Name
- Quantech Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- September 23, 2016
- Registry status as of
- December 11, 2025
- Latest entry
- December 10, 2025
- Founding act
- AKT NOTARIALNY Z DNIA 12.05.2016R., REPERTORIUM A NR 930/2016, NOTARIUSZ ANETA SZKUTNIK, KANCELARIA NOTARIALNA ANETA SZK…
Articles of association history (1)
- May 12, 2016: AKT NOTARIALNY Z DNIA 12.05.2016R., REPERTORIUM A NR 930/2016, NOTARIUSZ ANETA SZKUTNIK, KANCELARIA NOTARIALNA ANETA SZKUTNIK NOTARIUSZ W WARSZAWIE; AKT NOTARIALNY Z DNIA 20.06.2016R., REPERTORIUM A NR 1167/2016, NOTARIUSZ ANETA SZKUTNIK, KANCELARIA NOTARIALNA ANETA SZKUTNIK NOTARIUSZ W WARSZAWIE, ZMIANA PAR. 9, AKT NOTARIALNY Z DNIA 15.09.2016R., REPERTORIUM A NR 1935/16, NOTARIUSZ ANETA SZKUTNIK, KANCELARIA NOTARIALNA ANETA SZKUTNIK NOTARIUSZ W WARSZAWIE, ZMIANA PAR. 3
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- UL. 3 MAJA, 5, 05-080, IZABELIN B, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWSKI ZACHODNI
- AWOJ25@HOTMAIL.COM
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2863, 20.8293approx.
Risk and payment profile - Quantech
Credibility rating
5 / 100
Very poor credibility
Insolvency risk
suspended
Significant formal threat
Closure risk
80
/ 100
Extremely high risk
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/10 yrs
Board changes
1
1/10 yrs
PKD changes
0
0/10 yrs
Name changes
0
0/10 yrs
Data from 10 years of registry activity.
Credibility history
Payment reliability score from 2018–2020
Current: S (5/100)
Trend: stable (0.0 pts/year)
Spółka jest obecnie zawieszona – działalność operacyjna wstrzymana, wskaźnik wiarygodności odzwierciedla stan przed zawieszeniem.
Trade credit limit history
Standard limit from 2018–2020
Current: 0 PLN
Safe: 0 PLN
Operational status - Quantech
Founded
September 23, 2016
9 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
IZABELIN B
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
100 shares total
Shareholders
3
shareholders
Board
1 person
Filed years
2 years
2018–2020 · profitable: 0/2
Registry entries
16
latest: December 10, 2025
Risk signals
Revenue
0 PLN
2020
Net profit
-437 PLN
2020
Assets
13.2 K PLN
2020
Equity
-66.8 K PLN
2020
Valuation
0 PLN
suspended
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Quantech.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
